CA2297153C - Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders - Google Patents

Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders Download PDF

Info

Publication number
CA2297153C
CA2297153C CA002297153A CA2297153A CA2297153C CA 2297153 C CA2297153 C CA 2297153C CA 002297153 A CA002297153 A CA 002297153A CA 2297153 A CA2297153 A CA 2297153A CA 2297153 C CA2297153 C CA 2297153C
Authority
CA
Canada
Prior art keywords
carnitine
alkanoyl
acid
adhd
attention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002297153A
Other languages
English (en)
French (fr)
Other versions
CA2297153A1 (en
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CA2297153A1 publication Critical patent/CA2297153A1/en
Application granted granted Critical
Publication of CA2297153C publication Critical patent/CA2297153C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002297153A 1997-07-22 1998-07-08 Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders Expired - Fee Related CA2297153C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/898,433 1997-07-22
US08/898,433 US5869528A (en) 1997-07-22 1997-07-22 Therapeutical method for the treatment of attention-deficit/hyperactive disorders
PCT/IT1998/000188 WO1999004785A1 (en) 1997-07-22 1998-07-08 Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders

Publications (2)

Publication Number Publication Date
CA2297153A1 CA2297153A1 (en) 1999-02-04
CA2297153C true CA2297153C (en) 2007-07-03

Family

ID=25409451

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002297153A Expired - Fee Related CA2297153C (en) 1997-07-22 1998-07-08 Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders

Country Status (12)

Country Link
US (1) US5869528A (https=)
EP (1) EP0998276B1 (https=)
JP (1) JP4276779B2 (https=)
KR (1) KR100530879B1 (https=)
AT (1) ATE290376T1 (https=)
AU (1) AU735697B2 (https=)
CA (1) CA2297153C (https=)
DE (1) DE69829290T2 (https=)
ES (1) ES2237842T3 (https=)
NZ (1) NZ501966A (https=)
PT (1) PT998276E (https=)
WO (1) WO1999004785A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DK0951909T4 (da) 1998-03-19 2011-01-24 Sigma Tau Ind Farmaceuti Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf
US6204291B1 (en) 1998-06-26 2001-03-20 The Iams Company Process for promoting weight loss in overweight dogs
US6630159B2 (en) * 1999-02-23 2003-10-07 The Procter & Gamble Company Limiting weight gain of cats by feeding carbohydrate source that excludes rice
US7001618B1 (en) 1999-07-09 2006-02-21 The Iams Company Nutritional composition for weight management
WO2001028554A1 (en) * 1999-10-20 2001-04-26 Thomas Jefferson University Treatment of attention deficit disorder and impaired visual-spatial function with androgen
ITRM20010218A1 (it) * 2001-04-23 2002-10-23 Sigma Tau Healthscience Spa Composizione per la prevenzione o il trattamento dei disturbi dell'apprendimento in bambini affetti da deficit dell'attenzione ed iperattivi
JP4812968B2 (ja) * 2001-06-06 2011-11-09 太陽化学株式会社 注意欠陥多動性障害改善用組成物
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
AU2016219070B2 (en) 2015-02-13 2020-06-11 Mars, Incorporated Pet food feeding system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism

Also Published As

Publication number Publication date
US5869528A (en) 1999-02-09
HK1028546A1 (en) 2001-02-23
KR20010022008A (ko) 2001-03-15
JP4276779B2 (ja) 2009-06-10
WO1999004785A1 (en) 1999-02-04
EP0998276B1 (en) 2005-03-09
AU8240598A (en) 1999-02-16
ATE290376T1 (de) 2005-03-15
AU735697B2 (en) 2001-07-12
PT998276E (pt) 2005-06-30
ES2237842T3 (es) 2005-08-01
DE69829290D1 (de) 2005-04-14
CA2297153A1 (en) 1999-02-04
DE69829290T2 (de) 2006-04-13
NZ501966A (en) 2001-12-21
JP2001510800A (ja) 2001-08-07
KR100530879B1 (ko) 2005-11-23
EP0998276A1 (en) 2000-05-10

Similar Documents

Publication Publication Date Title
US5658590A (en) Treatment of attention-deficit/hyperactivity disorder
US6372790B1 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
CH641673A5 (it) Composizione farmaceutica comprendente una acil-carnitina per il trattamento del rallentato metabolismo cerebrale.
CA2297153C (en) Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
US6046193A (en) Treatment of attention-deficit/hyperactivity disorder
EP0552240B1 (en) New method of treating depression
JPS6241688B2 (https=)
Wilens et al. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine
Starkstein et al. Apathy and depression following stroke
HK1028546B (en) Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
MXPA00000441A (en) Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
Fann et al. Effect of antidepressant and antimanic drugs on amine uptake in man
Parnetti et al. Aniracetam (Ro 13-5057) for the treatment of senile dementia of Alzheimer type: Results of a multicentre clinical study
US2678899A (en) Stable solution of physostigmine
Roshanzamiri et al. Serotonin Syndrome due to Concomitant use of Linezolid and Methadone
CN120437129A (zh) 组合物在制备用于改善认知能力方面的药物中的用途
Maimon et al. Management of acute alcohol withdrawal
Boles et al. The Neuroleptic Malignant Syndrome
Fleet et al. Double-Blind Comparison of Bupropion
Greos PARADOXICAL BRONCHOCONSTRICTION WITH NEBULIZED ALBUTEROL BUT NOT WITH TERBUTALINE
MXPA00007739A (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
MXPA97005117A (en) Use of tomoxetine for the manufacture of a medicine for the treatment of the disorder of deficitde the attention / hyperactivi

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130709